Potential linkage between DPP ‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer

AbstractDipeptidyl peptidase (DPP) ‐4 inhibitors, a class of oral hypoglycemic agents, are widely used, especially in Asian populations, as they have been shown to be well‐tolerated and to cause relatively few hypoglycemic events despite exerting a potent glucose‐lowering effect by promoting endogenous insulin secretion, beside s also having extra‐pancreatic effects. Meanwhile, use of DPP‐4 inhibitors has been reported to be associated with the development of bullous pemphigoid (BP), a rare autoimmune blistering skin disease1, even though the absolute increase in the risk of development of BP is relatively low.

Source: Journal of Diabetes Investigation - November 26, 2019 Category: Endocrinology Authors: Jun Shirakawa, Yasuo Terauchi Tags: Commentary Source Type: research